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All UK H&I laboratories and transplant units operate under a single national kidney
offering policy, but there have been variations in approach regarding when to under-
take the pre-transplant crossmatch test. In order to minimize cold ischaemia times for
deceased donor kidney transplantation we sought to find ways to be able to report a
crossmatch result as early as possible in the donation process. A panel of experts in
transplant surgery, nephrology, specialist nursing in organ donation and H&I (all rel-
evant UK laboratories represented) assessed evidence and opinion concerning five
factors that relate to the effectiveness of the crossmatch process, as follows: when
the result should be ready for reporting; what level of donor HLA typing is needed;
crossmatch sample type and availability; fairness and equity; risks and patient safety.
Guidelines aimed at improving practice based on these issues are presented, and we
expect that following thesewill allowH&I laboratories to contribute to reducing CIT in
deceased donor kidney transplantation.
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1 INTRODUCTION
This document has been prepared by a working group set up at the
request of the British Transplantation Society (BTS). The workshop,
organized by the British Society for Histocompatibility and Immuno-
genetics (BSHI), was convened on 22 March 2019 in order to provide
guidance on crossmatching for kidney transplantation from deceased
donors in the United Kingdom. The brief was to resolve differences
in crossmatch practices in relation to when a result becomes available
(but not how crossmatching is performed). The overall aimwas tomini-
mize cold ischaemia time (CIT) and improvepatient outcomesby agree-
ing ways to enable a crossmatch test to be performed as early as possi-
ble in the donation process.
The United Kingdom has a single kidney offering policy that all
transplant units follow (ODT Policy POL186/10, 2019): we encour-
age the reader to be fully appraised of this document and consider
it when interpreting the following guidance. In this scheme, deceased
donor kidneys are offered according to rule-based procedures, being
regarded as a national asset while dependent on consent. The pol-
icy has been driven by notions of equality, equity and utility, and in
later years organ offering has attempted to find the acceptable bal-
ance between the latter two (Courtney&Maxwell, 2009). Donor organ
offering policies change with time due to developments in evidence,
politics, donation rates and waiting list demographics. There has been
a drift away from utility (e.g. HLA matching) and more towards equity
(e.g. to reduce variations in waiting time). How the UK kidney offer-
ing schemes have evolved has been reviewed recently (Watson et al.,
2020).
The current UKoffering schemewas introduced in September 2019
and involves complex, evidenced-based algorithms to give priorities
to waiting time and level of antibody sensitization to HLA (calculated
reaction frequency, cRF or panel reactive antibodies, PRA). These two
factors are of course related; highly sensitized patients have tended to
wait longer than less sensitized patients. This means less concern with
HLA mismatches, which is supported by evidence showing a reduced
influence of HLA matching on transplant outcomes (Su et al., 2004).
The waiting list patients are in one of two tiers. Patients with a cRF of
100% (99.5% or greater), or thosewith awaiting time of seven ormore
years, or with a matchability (measure of difficulty to match relative
to the previous 10,000 deceased donors) score of 10 are included in
Tier A, the top priority. The remainder are included in Tier B and offer-
ing is then determined by an accumulated point score taking into con-
sideration: donor–recipient risk index combinations; waiting time from
earliest of dialysis or activation on the list; tissue match and age com-
bined; location; matchability; total mismatch and blood group match.
This applies to kidneys from both circulatory death (DCD) and brain
death (DBD) donors.
Increased organ offering to highly sensitized patients and a greater
proportion of DCD donors raises the need to improve our systems for
delivering accurate, effective and timely pre-transplant crossmatching.
Particularly with the increased proportion of DCD donors, where cold
ischaemia time less than 12 h is a recognized determinant of outcome
(Summers et al., 2010), there is a benefit in reducing the time from
offering to transplantation, and howwe undertake the crossmatch can
contribute to the extent of this period (Taylor et al., 2010). Irrespective
of the details of the allocation or offering policy, the process of cross-
matching begins once a specific, potential recipient has been identified.
This process involves getting the right people, the right materials and
the right information together at the right time, and these guidelines
are concernedwith optimizing that process.
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Safe renal transplantation requires, amongst other things, pre-
transplant assessment of antibody compatibility (meaning an absence
of antibodies that are harmful, either directly or by virtue of their
being a biomarker of poor outcome). Compatibility can be determined
directly by testing the reaction in a crossmatch (XM) between recipient
serum and donor cells, typically leucocytes (LXM). The LXM can be
performed using cells from donor lymph nodes or spleen, or donor
peripheral blood lymphocytes (PBLs). Lymph nodes and spleen are
only available after organ retrieval, whilst PBLs can be taken from the
potential organ donor prior to removal of the kidneys. Alternatively,
HLA antibody compatibility can be assessed by prediction when a
recipient’s HLA-specific antibodies have been sufficiently character-
ized and the donor’s corresponding HLA alleles have been identified
(the virtual crossmatch, VXM).
All UK H&I laboratories regularly test waiting list patient samples
from the transplant units they support (routine threemonthly samples,
BSHI & BTS Guideline, 2015) and the results are reported to the cen-
tral deceaseddonororganoffering agency (NHSBT,ODT). Initial kidney
offering also includes a computer algorithm that compares the listed
unacceptable antigens (mostly basedonantibody specificities)with the
donor HLA type: essentially a virtual crossmatch. This minimizes the
chance of a subsequent positive crossmatch following the donor offer
and allocation.
Because the decision to proceed with deceased donor kidney trans-
plantation cannot bemade before theHLAXMresult is reported,many
of the planning decisions leading to and allowing the transplant to take
place also cannot be made until this result is available. Timely XM
reporting is therefore an essential component of an effective trans-
plantation system where there is national sharing of deceased donor
kidneys.
The introduction of the lymphocytotoxic crossmatch assay (Patel &
Terasaki, 1969) was a step change in the field of transplantation as this
demonstrated an increased incidence of hyperacute rejection in recip-
ients with a positive complement dependent lymphocytotoxic cross-
match. Over the decades, improvements in laboratory techniques,
immunosuppression and clinical management of both recipients and
donors have led to year-on-year improvements in both graft and
patient survival (Collaborative Transplant Study (CTS) K-14101-0820;
Collaborative Transplant Study (CTS) K-14102-0820). Challenges still
remained on the length of CIT for organs and the contribution of
CIT to delayed graft function (DGF) in transplant recipients (Perico
et al., 2004; Salahudeen et al., 2004; Siddiqi et al., 2004). Implemen-
tation and development of the H&I laboratory’s pre-transplant LXM
testing have, along with other factors such as timely access to the-
atres, helpedmake CIT amodifiable factor which directly reduces DGF
(Kolonko et al., 2011; Shrestha et al., 2016; Vacher-Coponat et al.,
2007).
In order to address this, laboratories began to consider whether
there were certain scenarios in which they could predict, with suf-
ficient confidence, the absence of damaging IgG HLA-specific anti-
bodies directed against donor mismatches (Taylor et al., 2000). Early
adopters of this were the Cambridge Transplant Unit (Taylor et al.,
2010) who referred to a pre-transplant compatibility assessmentwith-
out the need for day of transplant testing as a ‘virtual crossmatch’. In
these early publications, the recipient groups were carefully defined
with the majority being males with no sensitizing events and negative
for HLA-specific antibodies. Other centres adopted VXM policies and
there are many publications in the literature across the world detail-
ing different approaches to this in order to minimize CIT (Jani et al.,
2017; Rohan et al., 2020; Turner et al., 2019). The work from Taylor
et al. (2000) suggests a saving inCITof at least3h is achievable if aVXM
is used instead of a crossmatch requiring donor leucocytes, and this
was also associatedwith a reduced incidence of delayed graft function.
A heightened interest in VXM developed in the United States in 2014
with the implementation of the new Kidney Allocation Scheme which
increased sharing of organs across greater distances (Morris et al.,
2019). Similarly, in the United Kingdom, the kidney offering scheme
updated in 2019 gives national priority to highly sensitized patients
(HSPs) with shipping of kidneys from DCD and DBD donors across
the country (ODT Policy POL186/10, 2019). Availability of a VXM has
also helped adoption of the kidney fast-track offering scheme in the
United Kingdom, although this has tended to favour the less sensitized
patients (Callaghan et al., 2017).
The detection of IgG HLA-specific antibodies has evolved through
flow cytometry, ELISA, Luminex screening and single antigen bead
(SAB) assays, as summarized in a review by South and Grimm (2016).
The increasing sensitivity of antibody detection has concurrently
required a more detailed understanding of the limitations of solid
phase assays, namely the presence of cryptic epitopes; non-specific
binding; high-dose hook effect and differences between manufactur-
ers (Kumar et al., 2021; Middleton et al., 2014; South & Grimm, 2016)
because these are used to predict compatibility. Antibody assays based
on detection against single antigens are clearly a significant enabler of
general use of the virtual crossmatch. In part this is because of their
sensitivity (the confidence in the assignment of negative, or null reac-
tions) and also because this overcomes the inaccuracies in interpre-
tation due to the confounding effect of multiple antigens and linkage
disequilibrium seen with cell panel detection (Bingaman et al., 2008).
This certainly requires an in-depth understanding of the shortcom-
ings of the sources of error, but overall, we should be assured that
we have the tools to make the VXM a safe practice, in part because
there is likely to be a bias towards caution. Hence the unresolved mat-
ter of the definition of a positive threshold measurement, a critical
issue because the difference between negative and positive will influ-
ence both clinical outcome and access to transplantation. There is a
range of threshold values used in different HLA laboratories for bead
assays and with no consensus, but attempts are being made define
more objective measures of positivity as well as understand the rela-
tionships between measured levels and outcomes (Wisse et al., 2019;
Zecher et al., 2018). These issues also apply to other ways of detecting
and measuring donor-specific antibodies that have not been formally,
clinically validated.
Parallel to this, HLA typing methodologies have evolved with the
introduction of rapid DNA-based testing, such as PCR-SSP, PCR-SSOP
and subsequently, real-time PCR (or q-PCR), which permit typing
of HLA-A, -B, -C, -DRB1/3/4/5, -DQ and –DP, enabling a detailed
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characterization of HLA for deceased donors in a rapid timeframe.
More recently, methodologies that can provide DNA sequencing in
the required time frame have been developed (De Santis et al., 2020),
including full length HLA gene sequencing (Stockton et al., 2020). The
latter approach has the potential to eliminate all interpretation ambi-
guities. Within the United Kingdom, the field has reached a stage
where donors are required to be characterized at least for HLA-A, -
B, -C, DRB1/3/4/5, -DQB1 and -DPB1 (ODT datasheet DAT2885/3,
2019).
While the majority of UK laboratories now offer the VXM, there
may be differences between laboratories in both the acceptance cri-
teria and practice for patient management to support using a VXM.
Some will undertake a truly virtual (in silico) XM with no day of trans-
plant sample testing required. Others will perform a day of transplant
Luminex antibody test to facilitate a VXM. In all situations, the effec-
tive use of a VXM is dependent on correct and adequate donor HLA
typing together with up to date information regarding the potential
recipient’s HLA antibody screening and sensitization history (Sullivan
et al., 2018; Kumar et al., 2021). There were initial concerns that the
exclusive use of sensitive assays such as SAB to facilitate a VXM may
lead to excessive waiting times in the highly sensitized patient pop-
ulation (Meier-Kriesche & Kaplan, 2002) as lower immunological risk
recipients may be transplanted preferentially. More recent publica-
tions demonstrate a VXM is possible in these patient groups (Jaramillo
et al., 2020; Turner et al., 2019; Valentin et al., 2016) or may actually
increase access to transplantation for highly sensitizedpatients (Binga-
man et al., 2008).
Scenarios where a VXM may not be possible include situations
where a patient lacks up to date screening (Roll et al., 2020); where
there is insufficient information about sensitizing events to be able
to accurately predict risk; those highly sensitized patients with par-
ticularly complex HLA antibody profiles (Turner et al., 2019) and the
situations where all the relevant HLA loci have not been sufficiently
characterized in the donor. Essentially, this is dictated by the confi-
dence in being able to predict antibody compatibility (Taylor et al.,
2000). The BSHI & BTS guideline document (BSHI & BTS Guideline,
2015) describes circumstances where use of a VXM may or may not
be appropriate. For those cases where there is insufficient confidence
to use a VXM it is still important to minimize CIT due to the detrimen-
tal impact this has on the organ (Shrestha et al., 2016), and this could
be achieved by undertaking a LXM using pre-donation PBLs. Irrespec-
tive of themanner of crossmatching, the H&I laboratory should always
request confirmation from the transplant unit that no potential sensi-
tizing event has occurred since or just before the date of the last avail-
able sample. When a prospective LXM is used and found to be positive
(due to HLA antibodies), it is essential that this has been determined
as soon as possible (ideally prior to organ retrieval) to facilitate timely
re-offering of the kidney to other patients on the national transplant
waiting list for deceased donor kidneys.
The bead and leucocyte binding assays are profoundly different, not
just in terms of sensitivity. Both assays have been designed and val-
idated for the detection of HLA-specific antibodies but may be sub-
ject to non-HLA reactivity. In particular, leucocytes carry an additional
range of allo- and auto-antigens, many unknown, and generally with
their clinical significance untested. For this reason, a retrospective
LXM of a negative prospective VXM test may, on occasions, be posi-
tive, and this will be due to non-HLA. Such a retrospective test will of
course not influence donor allocation, andwewouldwelcome a formal,
multi-centre assessment of the value of retroactive verification of the
VXM.
A pre-transplant crossmatch to detect non-HLA (and non-ABO)-
specific antibodies is currently problematic for two main reasons. If
a target cell is used, then this must be known to express the rele-
vant antigen or antigens. This approach has been tested for potential
endothelial cell markers but the evidence that such a test is predic-
tive of rejection or transplant outcome is mixed (Breimer et al., 2009;
Zitzner et al., 2013;Daniel et al., 2016). In addition, the cells used in the
crossmatch, whether third party or a precursor in the endothelial cell
lineage, may not fully represent the antigen load of the donor’s actual
graft endothelium. Antibodies specific to the human neutrophil anti-
gen (HNA) system have also been implicated in transplant rejection.
BothTandB lymphocytes are known toexpressHNA-3, and antibodies
against this can cause a positive crossmatch in the absence ofHLAanti-
bodies (Key et al., 2019). HNA-3 sensitization is pregnancy associated,
so these antibodies are mostly restricted to parous individuals. Others
have shown that a positive LXMcan be associatedwith the presence of
certain non-HLA autoantibodies, but it is not evident that these are the
cause of the crossmatch reaction, and rejection is only seen in aminor-
ity of such cases (Kang et al., 2021).
The second problem lies with being able to define a positive XM
result in the absence of a known, corresponding antigen. For autoan-
tibodies, incompatibility can be assumed. For non-HLA (and non-ABO)
alloantibodies, a specific incompatibility cannot be deduced as, cur-
rently, deceased donors are only typed for HLA, ABO and Rh. Pre-
transplant testing of these antibodies, whether allo or auto, is also
required to reliably interpret a XM, and essential for a VXM, but this
is not routinely undertaken in the United Kingdom as the level of
evidence was insufficient at the time of development of the relevant
guidelines (BSHI&BTSGuideline, 2015; Tait et al., 2013). Transplanting
across unknown, non-HLA antibodies is therefore the general, current
practice in the United Kingdom. There are anecdotal reports of hyper-
acute rejection being associated with non-HLA and non-ABO incom-
patibilities, such as those involving other red cell-specific antibodies
(Shaw et al., 2019), but this is rare. Treatment of rejection associated
with non-HLA antibodies can be effected by the same agents and pro-
cedures used against HLA antibody-mediated rejection (reviewed by
Kardol-Hoefnagel &Otten, 2021).
This guideline has been created to help each laboratory optimize
their own processes in order to reduceCIT andmaximize the chance of
an allocated donor organ proceeding to transplantation. This is based
on evidence and opinion concerning safety, efficient use of resources
and logistics, effective use of all donor organs and fairness and equity
of access to transplantation. Althoughwritten specifically for deceased
donor kidney transplantation, the principles included are also applica-
ble to other forms of transplantationwhere pre-transplant assessment
of antibody compatibility is required, for example simultaneous kidney
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and pancreas transplantation. Furthermore, the objectives underlying
kidney allocation will be subject to future development. Indeed, the
most recent UK offering scheme was published soon after these
guidelines were prompted. However, offering changes are unlikely
to determine the validity of this document as the guidance relates to
events following donor offering, and a review of the current scheme in
this context confirms this. The technical details of how crossmatches
are actually performed were not reviewed by the working group and
so are outside the scope of this guideline.
2 GRADING OF RECOMMENDATIONS
These guidelines represent consensus opinion from experts in the field
of transplantation in the United Kingdom and represent a snapshot of
evidence available at the time ofwriting. It is recognized that some rec-
ommendations are made even when the evidence is weak. It is felt that
this is helpful to clinicians in daily practice.
In these guidelines the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) system has been used
to rate the strength of evidence and the strength of recommen-
dations (Atkins et al., 2004). The approach used in producing the
present guidelines is consistent with that adopted by Kidney Dis-
ease Improving Global Outcomes (KDIGO) (Uhlig et al., 2006). Explicit
recommendations are made on the basis of the trade-offs between
the benefits on one hand, and the risks, burden and costs on the
other.
For each recommendation the quality of evidence has been graded
as A (high), B (moderate), C (low) or D (very low):
Grade A evidence means high-quality evidence that comes
from consistent results from well-performed randomized
controlled trials or overwhelming evidence of another sort
(such as well-executed observational studies with very strong
effects).
Grade B evidence means moderate-quality evidence from ran-
domized trials that suffer from serious flaws in conduct, con-
sistency, indirectness, imprecise estimates, reporting bias or
some combination of these limitations, or from other study
designs with special strength.
GradeCevidencemeans low-quality evidence fromobservational
evidence, or from controlled trials with several very serious
limitations.
GradeD evidence is based only on case studies or expert opinion.
For each recommendation, the strength of recommendation has
been indicated as one of:
Level 1 (we recommend)
Level 2 (we suggest)
Not graded (where there is not enough evidence to allow formal
grading)
A Level 1 recommendation is a strong recommendation to do (or not
to do) something where the benefits clearly outweigh the risks (or vice
versa) for most, if not all patients.
A Level 2 recommendation is a weaker recommendation, where
the risks and benefits are more closely balanced or are more
uncertain.
3 OBJECTIVES AND RECOMMENDATIONS
Objective 1. Address the impact of the reporting time of a crossmatch
on the overall time in the transplant pathway. The key issues identified
are, first, where a prospective crossmatch is required; a transplant can-
not proceed until said crossmatch is completed. Second, in the United
Kingdom, the positive crossmatch rate is around 2.5% (based on data
between 2010 and 2015) (ODT Statistics and reports) and the organs
in these cases require re-offering and potentially a further crossmatch.
Third, there are logistical issues around access to theatres for trans-
plantation with kidney transplantation not always being given suffi-
cient priority for operating theatre availability. Therefore, the availabil-
ity of a crossmatch result ahead of organ arrival is an aid to surgical
planning.
3.1 Recommendations
1. To overcome this, we recommend that a crossmatch result (either
VXMor LXM) for a particular recipientmust be reported before the
organ arrives at the transplant centre, both LXM and VXM proce-
dures will allow this (Grade 1B).
2. If a VXM is not possible then we recommend that where possible,
pre-retrieval donor blood samples must be used when a LXM is
required (Grade 1B).
Objective 2. Overcome concerns around quality assurance and
accuracy of deceased donor HLA typing and virtual crossmatch-
ing strategies. It is now recognized that alloantibodies can be
stimulated by all the classical, polymorphic HLA proteins (HLA-A,
-B, -C, -DRB1/3/4/5, -DQA1, DQB1, DPA1 and –DPB1) (Duques-
noy, Marrari et al., 2014, 2014b). Donor typing to this degree is
therefore necessary to enable universal assessment of HLA anti-
body compatibility and adoption of the VXM, even though, in many
cases, this may not be necessary because for individual recipi-
ents, where the antibody repertoire tends to be limited, the min-
imum required HLA typing for safe transplantation would corre-
spond to the same loci as those against which the antibodies are
reacting.
In 2017, there was 0.8% error rate in the HLA types used for
deceased donor allocation in the United Kingdom (ODT, KAG ODT,
KA2018) and in 2/17 cases the errors affected the allocation sequence.
In 2018, the error rate was 0.3% and none of the errors affected the
allocation sequence (ODTKAG, 2019).
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3.2 Recommendations
1. We recommend that full HLA typing (HLA-A, -B, -C, -DRB1/3/4/5,
-DQA1, DQB1, DPA1 and –DPB1) is generally required for cross-
match interpretation (Tait et al., 2013). This is more extensive
than the current minimum level of HLA resolution required for
UK deceased donor allocation (ODT datasheet DAT2885/3, 2019)
(Grade 1A). However, it is self-evident that all-inclusive, unambigu-
ous and the highest resolution HLA typing widens the safe use of
the VXM as well as improving the reliable interpretation of cross-
matches in general.
2. In order to correctly classify a negative VXM or identify a false-
positive LXM result, typing for HLA loci corresponding to those
represented in the recipient’s antibody profile must be available
(Alzahrani et al., 2019; Tambur et al., 2010) (Grade 1A).
3. Where a recipient has uncharacterized HLA-specific antibodies,
or has a defined antibody but there is an incomplete donor HLA
type (in relation to a recipient’s antibody specificities, e.g. recipient
has allele-specific antibodies), or where the intended recipient has
known donor HLA-specific antibodies, a pre-transplant LXM must
be performed (Grade 1B).
4. A retrospective LXM(e.g. using cells fromthedonor spleenor lymph
node) may be undertaken when a pre-transplant VXM has been
used. However, if an audit of sufficient cases shows concordance
between the initial VXMs and subsequent LXMs then the latter can
be safely omitted (Grade 2B).
Objective 3. Address issues relating to donor sample availability
and quantity. The timeliness of reporting a prospective crossmatchwill
depend on early taking of donor blood samples arranged in advance
between the laboratory, clinical and donation teams. There are many
demands for donor blood samples and anecdotal evidence suggests
that excessive blood taking may be harmful to the donor and compro-
mise their donated organs.
3.3 Recommendations
1. We recommend that peripheral blood for crossmatch testing must
only be requested and sent on demand. Therefore, when a VXM is
to be used, crossmatch samples must not be taken from the donor
pre-transplant (Grade 1B).
2. When PBLs for LXM are required, up to a maximum of 40 ml of
peripheral blood in EDTA should be requested unless there are
exceptional circumstances. In this scenario, the H&I laboratory
can request a volume as required for locally validated procedures
(Grade 1B).
3. Pre-retrieval crossmatch donor blood must be taken and sent as
expeditiously as possible (Grade 1B).
4. Spleen or lymph node samples must be taken at the time of organ
retrieval in all cases (e.g. to verify aVXMbyperforming a retrospec-
tive XM, or to enable LXM if the organ is transferred to secondary
accepting unit and VXM cannot be performed) (Grade 1A).
It should be noted that geographical considerations may need to be
taken into accountwhen considering feasibility of use of PBLs for LXM,
namely time and cost taken to ship the samples, particularlywhere long
distances are involved.
Objective 4. Ensure fairness and equity for all potential transplant
recipients as immunologically high-risk cases tend to wait the longest
for a transplant. The interpretation of a crossmatch in such cases tends
to be complex, requiring more information. A comprehensive and up-
to-date HLA serological history, according to national and other guide-
lines (BSHI & BTS Guideline, 2015; Tait et al., 2013) is therefore a pre-
requisite for an equitable approach where using a crossmatch to allow
a transplant to proceed.
3.4 Recommendations
1. We recommend that no patient must be advantaged or disadvan-
taged because of tractability of the use of a particular type of XMor
crossmatch policy (Grade 1A).
2. The crossmatch test should be regarded as an enabler of safe trans-
plantation, rather than primarily a tool to prevent transplantation,
particularly for sensitized patients and local policy developed with
this in mind (Bingaman et al., 2008) (Grade 2B).
Objective 5. When undertaking virtual crossmatching, there must
be a full understanding of the potential risks involved to ensure patient
safety is not compromised. All involved must understand that the pro-
files and levels of HLA-specific antibodies in individual patients can
change and the VXM is currently limited to testing compatibility for
HLA. The LXM can detect non-HLA antibodies, which may or may not
be clinically relevant; at the moment, there is insufficient evidence
to guide either way. Other donor-derived target cells can be used to
detect non-HLA, donor-specific antibodies (e.g. endothelial cell precur-
sors; Zitzner et al., 2013).
3.5 Recommendations
1. We recommend that if laboratories are not using HLA antibody
results from a sample collected on the day of evaluation, they must
have a rigorous mechanism for identifying any potential sensitiz-
ing events or changes in immunosuppressive therapy since the date
of the last tested sample (Grade 1A). This can be achieved through
the development of good working relationships between the clini-
cal team and the laboratory, and the process documented in local
policy.
2. Non-HLA donor-specific antibodies are outside the scope of this
guidance (Grade 2D).
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